NASDAQ:CRBU Caribou Biosciences Q3 2026 Earnings Results & Report $0.39 -0.03 (-6.38%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Caribou Biosciences beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.25 versus the -$0.2620 consensus estimate, while revenue of $1.61 million topped the $1.60 million estimate by $10.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call7:00 AM ET Caribou Biosciences EPS ResultsActual EPS-$0.25Consensus EPS -$0.2620Beat/MissBeat by +$0.0120One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersCaribou Biosciences Revenue ResultsActual Revenue$1.61 millionExpected Revenue$1.60 millionBeat/MissBeat by +$10.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Caribou Biosciences Q3 2026 Earnings FAQ Did Caribou Biosciences beat earnings estimates for Q3 2026? Caribou Biosciences (NASDAQ:CRBU) reported earnings of -$0.25 per share for Q3 2026, beating the consensus estimate of -$0.2620. The report was announced on Thursday, November 5, 2026. What was Caribou Biosciences' revenue for Q3 2026? Caribou Biosciences reported revenue of $1.61 million for Q3 2026, against a consensus estimate of $1.60 million. Caribou Biosciences Earnings HeadlinesCaribou Biosciences Reports Third Quarter 2026 Financial ResultsNovember 5, 2026 | finance.yahoo.comCaribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue EstimatesNovember 5, 2026 | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual MeetingNovember 4, 2026 | globenewswire.comCaribou Biosciences consensus price target decreased by 24.32% to $5.71November 2, 2026 | msn.comCaribou Biosciences (CRBU) Stock Fair Value Falls After Clinical Programs Are HaltedOctober 28, 2026 | finance.yahoo.comSee More Caribou Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email. Email Address About Caribou BiosciencesCaribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments. Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing. Its product candidates have included allogeneic chimeric antigen receptor T-cell (CAR-T) therapies targeting blood cancers, as well as programs exploring applications in multiple myeloma and solid tumors. The company’s development activities have focused on improving the persistence, activity and manufacturability of engineered immune cells. Founded in 2011, Caribou Biosciences is headquartered in Berkeley, California, and serves the global biotechnology and pharmaceutical markets through its research and clinical-development programs. Rachel Haurwitz, Ph.D., is a co-founder and has served as the company’s president and chief executive officer. Caribou’s common stock trades on the Nasdaq under the symbol CRBU.View Caribou Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
